


Ask a doctor about a prescription for Piracetam Espefa
Piracetam
Piracetam Espefa is a nootropic medicine. It reduces blood viscosity, increases blood flow through brain vessels without dilating them. It also increases oxygen utilization and glucose consumption in ischemic brain tissue.
Before starting to take Piracetam Espefa, discuss it with your doctor:
Special caution should be exercised in patients:
Do not suddenly stop taking piracetam in patients being treated for myoclonus, to avoid recurrence of myoclonus or generalized seizures.
Tell your doctor or pharmacist about all medicines you are taking now or have recently taken, as well as any medicines you plan to take.
The patient should inform the doctor if they are taking any of the following medicines:
The likelihood of piracetam affecting the metabolism of other medicines is low.
Taking Piracetam Espefa with food, drink, and alcohol
The medicine can be taken during or between meals.
It is not recommended to drink alcohol while taking this medicine.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before taking this medicine.
Do not take this medicine during pregnancy, due to the lack of sufficient data on the use of piracetam in pregnant women.
Do not take this medicine during breastfeeding, as it passes into breast milk.
The medicine may affect your ability to drive and operate machines. If you experience drowsiness, dizziness, do not drive or operate machines.
Piracetam Espefa contains carmoisine(azo dye)
The medicine may cause allergic reactions.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
However, in the maximum daily dose (24 g of piracetam), it contains approximately 1.7 to 3 mmol (or 40 to 70 mg) of sodium (maximum daily sodium intake for adults recommended by WHO = 2 g).
Always take Piracetam Espefa exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
To plan and use the appropriate dosing regimen, Piracetam ESPEFA is also available in a dose of 800 mg.
1000 mg is equivalent to: 1 g.
One 1200 mg film-coated tablet is equivalent to: 1.2 g.
Treatment of cortical myoclonus
The initial dose is 2 tablets 3 times a day (7.2 g of medicine per day).
If necessary, the doctor may recommend gradually increasing the dose by 4.8 g of medicine per day every 3 or 4 days. The maximum daily dose is 20 tablets (24 g of medicine) given in divided doses, i.e., 2 or 3 times a day.
In combination therapy with other antiepileptic (antimyoclonic) medicines, the doses of other medicines should be maintained at the recommended therapeutic doses. If the patient's condition improves, the doctor may reduce the doses of other medicines (if possible).
In patients with myoclonus, the doctor may try to reduce the dose or discontinue the medicine every 6 months. To do this, the dose of the medicine should be reduced by 1.2 g of medicine every 2 days to prevent sudden recurrence of the disease.
Treatment of dyslexic disorders in children in combination with speech therapy
In combination with speech therapy in children and adolescents aged 8 to 13 years:
3.2 g of medicine per day in 2 divided doses.
Treatment of dizziness
2.4 g of medicine per day in 3 divided doses. The treatment lasts 8 weeks.
Use of Piracetam Espefa in patients with renal function disorders
The doctor may reduce the dose of piracetam in patients with renal function disorders.
Use of Piracetam Espefa in elderly patients
In elderly patients treated long-term with piracetam, the doctor will individually adjust the dose of the medicine after assessing kidney function.
If you take more of the medicine than you should, contact your doctor immediately.
Continue taking the medicine without increasing the next dose.
Do not take a double dose to make up for a missed dose.
Do not stop taking the medicine without consulting your doctor.
Stopping treatment with piracetam in patients with myoclonus increases the risk of seizures.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Piracetam Espefa can cause side effects, although not everybody gets them.
redness of the skin, swelling, hives, shortness of breath, swelling of the throat that makes breathing difficult. These are symptoms of an allergic reaction.
Frequent(occurring in 1 to 10 people in 100):
Uncommon(occurring in 1 to 10 people in 1000):
Frequency not known(cannot be estimated from available data):
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C,
02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton. The expiry date refers to the last day of the month.
Do not store above 25°C.
Store in the original package to protect from light and moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Piracetam Espefa is a pink, film-coated, oblong tablet.
The pack contains 60 film-coated tablets.
Chemiczno-Farmaceutyczna Spółdzielnia Pracy ESPEFA,
ul. J. Lea 208,
30-133 Kraków
Tel.: +48 12 639 27 27,
Fax: +48 12 639 96 45
Information for the blind and visually impaired:800-007-777
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Piracetam Espefa – subject to medical assessment and local rules.